| Literature DB >> 20144296 |
Abstract
Insulin remains the most effective and durable hypoglycemic agent for the treatment of diabetes. The addition of an effective oral insulin dosage form to the antidiabetes armamentarium may have significant benefits in terms of fostering compliance and adherence among patients, as well as physiologic advantages due to the fact that such a dosage form replicates the natural route of insulin secretion and absorption through the portal vein and targets the liver directly. Several companies have developed technological platforms that protect polypeptides and proteins from enzymatic hydrolysis, enable their transport across the epithelial lining, and promote their absorption from the gastrointestinal tract. A review of the potential physiological rationale and advantages, as well as of current pertinent technologies used specifically with insulin, is herewith provided. 2009 Diabetes Technology Society.Entities:
Mesh:
Substances:
Year: 2009 PMID: 20144296 PMCID: PMC2769870 DOI: 10.1177/193229680900300322
Source DB: PubMed Journal: J Diabetes Sci Technol ISSN: 1932-2968